Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code
Lacuna Pharma Pty Ltd
chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ruxolitinib Tablets, 20 mg, manufactured by Sun Pharmaceutical Industries Limited, India with JAKAVI (ruxolitinib) tablets 20 mg, (each Jakavi 20 mg tablet contains 26.40 mg of ruxolitinib phosphate equivalent to 20 mg of ruxolitinib). Imported by: Novartis Biociências SA Av. Prof. Vicente Rao, 90 - São Paulo - SP CNPJ: 56.994.502/0001-30. Manufactured by: Novartis Pharma Ste
Lacuna Pharma Pty Ltd
Myelofibrosis, polycythemia vera, acute and chronic graft-versus-host-disease.
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulosin Hydrochloride Capsules USP 0.4 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Tamsulosin Hydrochloride extended-release capsules 0.4 mg, Product of Geolab Indústria Farmacêutica S/A, VP. 1B QD.08-B Modules 01 to 08, DAIA - Anápolis – GO, in healthy adult, human male subjects under fasting condition.
Lacuna Pharma Pty Ltd
Benign prostatic hyperplasia (BPH)
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulosin Hydrochloride Capsules USP 0.4 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Tamsulosin Hydrochloride extended-release capsules 0.4 mg, Product of Geolab Indústria Farmacêutica S/A, VP. 1B QD.08-B Modules 01 to 08, DAIA - Anápolis – GO, in healthy adult, human male subjects under fed condition.
Lacuna Pharma Pty Ltd
Benign prostatic hyperplasia (BPH)
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
Lacuna Pharma Pty Ltd
Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.
Lacuna Pharma Pty Ltd
Axial spondyloarthritis, Crohn’s disease, Ulcerative colitis, Atopic dermatitis, Rheumatoid arthritis, Psoriatic arthritis
1 trial -
An open label, randomized, crossover, two-period, two-sequence, multiple dose study to assess the relative bioavailability of Rotigotine 4.5 mg (2 mg/24 hrs) transdermal patch (Test Product) compared to Neupro® 2 mg/24 h Transdermal Patch (Reference product) in 48 healthy adult volunteers under fasting conditions.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a bioavailability study in healthy subjects).
1 trial -
An open label, randomized, crossover, two-period, two-sequence, single dose study to assess the relative bioavailability of Rotigotine 4.5 mg (2 mg/24 hrs) transdermal patch (Test Product) compared to Neupro® 2 mg/24 h Transdermal Patch (Reference product) in 48 healthy adult volunteers under fasting conditions.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a bioavailability study in healthy subjects).
1 trial -
An open label, randomized, single dose, two-sequence, two-treatment, four-period, fully replicate, cross-over pharmacokinetic study comparing Alverine citrate/Simeticone 60 mg/300 mg soft capsules to Meteospasmyl 60 mg/300 mg soft capsules in healthy male and female subjects under fed conditions.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a bioavailability study in healthy subjects)
1 trial -
An open, single arm, single-center, Phase 1 trial investigating the effect of 7-days-repeated administration of linaprazan glurate on the pharmacokinetics of repeated doses of an approved antibiotic in healthy participants
Lacuna Pharma Pty Ltd
Helicobacter pylori infection, GERD
1 trial -
An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).
Lacuna Pharma Pty Ltd
Glioblastoma
1 trial -
An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared with Nicorette® lozenge 4 mg in healthy adults who use cigarettes
Swedish Orphan Biovitrum Pty Ltd
Nicotine use
1 trial -
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
Lacuna Pharma Pty Ltd
inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.
1 trial -
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
Aramchol free acid tablet 600mg, single dose
Galmed Pharmaceuticals
Hepatic Impairment
1 trial -
Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)
Boehringer Ingelheim
Solid tumours with HER2 aberrations, Non-small cell lung cancer
1 trial -
Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
Atea Pharmaceuticals
Healthy Volunteer Study
1 trial -
Bioequivalence clinical trial of dapagliflozin 10 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions.
Laboratorios Tillomed Spain S.L.U
Diabetes
1 trial -
Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, single dose study with crossover design in healthy subjects
Orion Laboratories Pty.
short-term treatment of insomnia
1 trial -
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative design
Helsinn Birex Pharmaceuticals
Healthy volunteers
1 trial -
CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
The George Institute
Acute leukemia and myelodysplastic syndromes
1 trial -
CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer
The George Institute
Patients with recurrent and/or metastatic solid cancer.
1 trial -
Cannabidiol, Medium Dose
BRIGHT MINDS BIOSCIENCES INC.
Cannabis
1 trial -
DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy
Boehringer Ingelheim
relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources